Effect of Valsartan on chronic heart failure

Objective To observe the effect of valsartan on chronic heart failure. Methods Fifty-eight chronic heart failure patients were randomly divided into two groups: 30 patients treated with Valsartan(Valsartan group) and 28 patients received stardard therapies plus without Valsartan or any other angiotensinⅡ type 1 receptor blockade(control group).Both groups underwent echocardiography before and 6 months after treatment. Results In Valsartan group,left ventricular end-diastolic volume(LVEDV) [(102.6±25.6)ml vs.(117.2±28.5)ml,P0.05]and left ventricular end-systolic volume(LVESV) [(53.1±20.6)ml vs.(66.4±28.7)ml,P0.05] were significantly decreased after treatment while left ventricular ejection fraction(LVEF) [(56.1±9.6)% vs.(47.4±13.2)%,P0.01] was significantly increased.After one year's follow up,the rate of recurrent heart failure in Valsartan group was significantly lower than in control group(24.0% vs.46.7%,P0.05). Conclusions Valsartan can prevent ventriclular remolding and decrease recurrent heart failure.